FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120508732> ?p ?o ?g. }

• W3120508732 abstract "A class of phosphane gold(I) compounds, made of azoles and phosphane ligands, was evaluated for a screening on the regards of Breast Cancer cell panels (BC). The compounds possess N-Au-P or Cl-Au-P bonds around the central metal, and they differ for the presence of aprotic or protic polar groups in the azoles and/or the phosphane moieties to tune their hydrophilicity. Among the six candidates, only the compounds having the P-Au-N environment and not displaying neither the hydroxyl nor carboxyl groups in the ligands were found active. The compounds were screened by MTT tests in SKBR3, A17, and MDA-MB231 cancer cells, and two compounds (namely the 4,5-dicyano-imidazolate-1yl-gold(I)-(triphenylphosphane, 5, and 4,5-dichloro-imidazolate-1yl-gold(I)-triphenylphosphane, 6) were found very cytotoxic, with the most active with an IC 50 value of 3.46 μM in MDA-MB231 cells. By performing enzymatic assays in the treated cells lysates, the residual enzymatic activity of dihydrofolate reductase (DHFR) has been measured after cell treatment for 4 or 12 h in comparison with control cells. Upon 12 h of treatment, the activity of DHFR was significantly reduced in both SKBR3 and A17 cells by compounds 5 and 6, but not in human MDA-MB231 cells; interestingly, it was found remarkably high after 4 h of treatment, revealing a time dependence for the DHFR enzymatic assays. The DHFR inhibition data have been compared to those for the thioredoxin reductase (TrxR), the most recognized molecular target for gold compounds. For this latter, similar residual activities (i.e., 37 and 49% for the match of SKBR3 cells and compound 5 or 6, respectively) were found. Binding studies on the regards of ct-DNA (calf-thymus-DNA) and of plasma transporters proteins, such as BSA (bovine serum albumin) and ATF (apo transferrin), were performed. As expected for gold compounds, the data support strong binding to proteins (K sv values range: 1.51 ÷ 2.46 × 10 4 M −1 ) and a weaker interaction with ct-DNA's minor groove (K sv values range: 1.55 ÷ 6.12 × 10 3 M −1 )." @default.
• W3120508732 created "2021-01-18" @default.
• W3120508732 creator A5009628801 @default.
• W3120508732 creator A5012796096 @default.
• W3120508732 creator A5041594446 @default.
• W3120508732 creator A5054065502 @default.
• W3120508732 creator A5058727495 @default.
• W3120508732 creator A5059041711 @default.
• W3120508732 creator A5069913531 @default.
• W3120508732 creator A5073520034 @default.
• W3120508732 creator A5081180730 @default.
• W3120508732 date "2021-01-11" @default.
• W3120508732 modified "2023-10-01" @default.
• W3120508732 title "Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells" @default.
• W3120508732 cites W1489909616 @default.
• W3120508732 cites W1982566962 @default.
• W3120508732 cites W1982693310 @default.
• W3120508732 cites W1987228839 @default.
• W3120508732 cites W1991303607 @default.
• W3120508732 cites W1998067178 @default.
• W3120508732 cites W2004650064 @default.
• W3120508732 cites W2006924605 @default.
• W3120508732 cites W2010660231 @default.
• W3120508732 cites W2012834867 @default.
• W3120508732 cites W2016625300 @default.
• W3120508732 cites W2027437657 @default.
• W3120508732 cites W2029233845 @default.
• W3120508732 cites W2029434079 @default.
• W3120508732 cites W2034207473 @default.
• W3120508732 cites W2034696105 @default.
• W3120508732 cites W2038124483 @default.
• W3120508732 cites W2040836606 @default.
• W3120508732 cites W2048183684 @default.
• W3120508732 cites W2056677038 @default.
• W3120508732 cites W2058931976 @default.
• W3120508732 cites W2072829138 @default.
• W3120508732 cites W2074966669 @default.
• W3120508732 cites W2095157449 @default.
• W3120508732 cites W2096025266 @default.
• W3120508732 cites W2096057672 @default.
• W3120508732 cites W2122674062 @default.
• W3120508732 cites W2126504813 @default.
• W3120508732 cites W2129037053 @default.
• W3120508732 cites W2131505260 @default.
• W3120508732 cites W2138663673 @default.
• W3120508732 cites W2142486051 @default.
• W3120508732 cites W2142620503 @default.
• W3120508732 cites W2148550663 @default.
• W3120508732 cites W2153565541 @default.
• W3120508732 cites W2166880800 @default.
• W3120508732 cites W2214029008 @default.
• W3120508732 cites W2291411876 @default.
• W3120508732 cites W2332316166 @default.
• W3120508732 cites W2491458126 @default.
• W3120508732 cites W2523763608 @default.
• W3120508732 cites W2805631717 @default.
• W3120508732 cites W2889646458 @default.
• W3120508732 cites W2900598939 @default.
• W3120508732 cites W2903711622 @default.
• W3120508732 cites W2912993657 @default.
• W3120508732 cites W2922672762 @default.
• W3120508732 cites W2945855920 @default.
• W3120508732 cites W2970774790 @default.
• W3120508732 cites W2971836364 @default.
• W3120508732 cites W3054872185 @default.
• W3120508732 cites W3093825550 @default.
• W3120508732 cites W4293247451 @default.
• W3120508732 doi "https://doi.org/10.3389/fchem.2020.602845" @default.
• W3120508732 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7821381" @default.
• W3120508732 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33490036" @default.
• W3120508732 hasPublicationYear "2021" @default.
• W3120508732 type Work @default.
• W3120508732 sameAs 3120508732 @default.
• W3120508732 citedByCount "8" @default.
• W3120508732 countsByYear W31205087322021 @default.
• W3120508732 countsByYear W31205087322022 @default.
• W3120508732 crossrefType "journal-article" @default.
• W3120508732 hasAuthorship W3120508732A5009628801 @default.
• W3120508732 hasAuthorship W3120508732A5012796096 @default.
• W3120508732 hasAuthorship W3120508732A5041594446 @default.
• W3120508732 hasAuthorship W3120508732A5054065502 @default.
• W3120508732 hasAuthorship W3120508732A5058727495 @default.
• W3120508732 hasAuthorship W3120508732A5059041711 @default.
• W3120508732 hasAuthorship W3120508732A5069913531 @default.
• W3120508732 hasAuthorship W3120508732A5073520034 @default.
• W3120508732 hasAuthorship W3120508732A5081180730 @default.
• W3120508732 hasBestOaLocation W31205087321 @default.
• W3120508732 hasConcept C109316439 @default.
• W3120508732 hasConcept C121608353 @default.
• W3120508732 hasConcept C178790620 @default.
• W3120508732 hasConcept C181199279 @default.
• W3120508732 hasConcept C185592680 @default.
• W3120508732 hasConcept C191560914 @default.
• W3120508732 hasConcept C202751555 @default.
• W3120508732 hasConcept C21951064 @default.
• W3120508732 hasConcept C2777737464 @default.
• W3120508732 hasConcept C2780596747 @default.
• W3120508732 hasConcept C2781320022 @default.
• W3120508732 hasConcept C2910496842 @default.
• W3120508732 hasConcept C2994423619 @default.

• next